23:41 , Jul 7, 2014 |  BC Extra  |  Financial News

Abzena raises L20 million in London IPO

Abzena Ltd. (LSE:ABZA) raised L20 million ($34 million) through the sale of 25 million shares at 80p in an IPO underwritten by Cenkos Securities. The price values the company at L77.9 million ($132.7 million). Abzena's...
07:00 , Jun 23, 2014 |  BioCentury  |  Finance

Abzena's AIM

Abzena Ltd. is following in the footsteps of other revenue-generating U.K. biopharma service companies by seeking a listing on the LSE's AIM market. CEO John Burt told BioCentury the listing will provide the company enough...
00:43 , Jun 17, 2014 |  BC Extra  |  Financial News

Service/technology provider Abzena files for London IPO

Abzena Ltd. (London, U.K.) proposed an IPO on the London Stock Exchange underwritten by Cenkos Securities plc. Abzena comprises two subsidiaries -- PolyTherics Ltd. and Antitope Ltd. PolyTherics offers site-specific conjugation technologies for antibody-drug conjugate...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Abzena, Alpha Cancer deal

Abzena's PolyTherics Ltd. subsidiary partnered with Alpha Cancer to develop drug conjugates to treat cancer. PolyTherics will use its ThioBridge linker technology to attach an undisclosed cytotoxic drug to Alpha Cancer's recombinant human alpha fetoprotein...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Abzena antibodies, drug delivery news

PolyTherics Ltd. renamed itself as Abzena Ltd. and said Abzena comprises two subsidiaries - PolyTherics and Antitope. The company will move PolyTherics' operations from London to Cambridge, U.K., where Abzena will also establish its headquarters....
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

MacroGenics, PolyTherics deal

PolyTherics and MacroGenics extended a 2010 deal to develop antibody-drug conjugates (ADCs). Under the extension, PolyTherics will apply its ThioBridge linker technology to attach different cytotoxic payloads to a range of bispecific antibodies from MacroGenics'...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Annexon, PolyTherics deal

Annexon partnered with PolyTherics' Antitope Ltd. subsidiary to generate antibodies to treat neurodegenerative diseases. Annexon will provide antibodies against undisclosed components of the complement system, and Antitope will use its Composite Human Antibody technology to...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

PolyTherics, Tube Pharmaceuticals deal

PolyTherics and Tube partnered to develop antibody-drug conjugates (ADCs) to treat cancer using PolyTherics' ThioBridge conjugation technology and Tube's cytotoxic synthetic tubulin binding agents called cytolysins. The companies will produce reagents to link antibodies to...
07:00 , Oct 21, 2013 |  BioCentury  |  Strategy

MedImmune's warheads

AstraZeneca plc 's latest pair of deals - the acquisition of Spirogen Ltd. and a partnership with ADC Therapeutics S.a.r.l. - gives the pharma's MedImmune LLC biologics unit all the tools it needs for antibody-drug...
07:00 , Aug 19, 2013 |  BioCentury  |  Product Development

The next wave in ADCs

After about 25 years of development, antibody-drug conjugates have gained acceptance as a validated approach to the targeted killing of cells, with two drugs approved in the past two years. While Seattle Genetics Inc. and...